All In Biotech

Free tool

FAERS Monitor: Inluriyo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218881 or its brand name (Inluriyo, Imlunestrant Tosylate). Reports on generic versions are filed under their own applications.

Reports

92

Serious

25

27% of reports

Hospitalization

8

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea9
  • malignant neoplasm progression8
  • nausea7
  • disease progression6
  • fatigue6
  • blood creatinine increased4
  • decreased appetite4
  • hospitalisation4
  • malaise4
  • pneumonia4
  • pruritus4
  • anaemia3
  • headache3
  • hot flush3
  • hyponatraemia3

Reports by year received

View as table
YearReports
20223
20232
20251
202686

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal817.99.2112
blood creatinine increasedSignal414.05.436
hyponatraemiaSignal312.24.021
disease progressionSignal611.65.348
hot flushSignal39.13.014
hospitalisationSignal46.02.312
decreased appetiteSignal43.91.56
anaemia33.61.23
diarrhoeaSignal93.21.712
pneumonia42.81.13
pruritus42.40.92
malaise42.10.81
nausea72.01.03
fatigue61.80.81
headache31.10.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.